SKYRIZI Abbvie Pty Ltd

SKYRIZI (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in children 6 years of age and older. Plaque psorias occurs when the immune system mistakenly attacks healthy skin cells causing them to rapidly turnover which leads to a buildup of cells on the skin's surface, forming thick, scaly plaques.